about
Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in HumansImmunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older personsSafety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSafety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variantEnrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Cytomegalovirus viral and antibody correlates in young childrenVancomycin use in hospitalized pediatric patients.Knowledge and awareness of congenital cytomegalovirus among womenRotavirus infection alters peripheral T-cell homeostasis in children with acute diarrhea.Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Catheter-related polymicrobial bloodstream infections among pediatric bone marrow transplant outpatients--Atlanta, Georgia, 2007.Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004.Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA humanEffect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA.Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial.Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.Assessing Agreement of Repeated Binary Measurements with an Application to the CDC’s Anthrax Vaccine Clinical TrialVANCOMYCIN USE IN PEDIATRIC CARDIOTHORACIC SURGERY PATIENTSProgress report--Georgia Immunization RegistryPost-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX and placebo versus PedvaxHIB and RECOMBIVAX HB in healthy infantsImmunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trialSafety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of ageResponse to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7"Invasive infections with Haemophilus influenzae serotype a containing an IS1016-bexA partial deletion: possible association with virulence2013 IDSA clinical practice guideline for vaccination of the immunocompromised host
P50
Q28391301-330A9354-4B85-40F6-B20F-BF34853A2C07Q30419062-F811145E-4280-4E9C-80F1-75174CB829F1Q30419240-4B5CAE40-78F1-408F-8521-BCCB7102C830Q33541763-0A201E2E-710B-472A-905F-EA367D5525DFQ33808135-EA461BBD-BF13-4F3D-B63E-BF2ADDF06055Q34159806-AA6DFCFB-3634-45C7-8841-11E25290EDDCQ34390072-0C976ACA-D745-4268-ABED-5DEA2E68B6D2Q34537615-0F8C976D-E6DB-4058-8DD6-2183D049E29FQ35191020-611EDBD1-3423-4F92-9350-0AB0C55E1A0DQ35606135-DBA291E0-7CA4-4DBA-B935-7CAA61F0E2C9Q35785249-D6846EC7-9831-4E51-8695-8F370EE8AE7CQ36009663-E1485F48-A2EA-4A7F-B8AB-7A55C4F32BA8Q36031220-7C710AE2-CBAA-4F91-B5A3-FB8A508FBBAEQ36600323-08B6DECE-3290-4C2B-9CF5-C30C20BD78A0Q37720723-80869E40-D73C-4D2D-9980-26D716A4CB05Q38386808-F8AB750F-8CF4-4121-85A8-D6B6858DE4E7Q40265657-7F2A899B-38BE-4186-AC81-4A6ADED4A39AQ40456591-27332C16-81F2-47B6-ACB2-5077AE02B499Q40541369-15BA3869-3B43-43C6-9ED2-1DD31FCF4695Q41122192-21E5C431-0753-4386-BE00-907A952476FEQ42217708-55714EF8-CCD4-420E-9510-CD445A857DC9Q42246468-899BA7C8-E397-4EA8-8DBC-2AF4566F6977Q44297905-C6063360-EF5E-4759-BC1F-5D4A169A0956Q45106083-475C6ABD-0E8C-461D-B8FC-80D1DD7F8D89Q47365760-3D03451C-EE69-4CB3-82B0-D597C2E1CDFAQ51988230-BFC80B8C-E6B5-4F92-8480-A734604AC97EQ53914329-31DE33C2-54EA-44D8-9A91-04F037C67F8FQ57157648-195A5CC5-F2FC-4F0B-8B6C-0DDCB217029EQ61409279-ED935BBE-2776-47C8-8247-B1A386F11A1EQ74636385-87B20821-4E7C-4C1B-B274-3A9DB5319935Q78569838-320A72C3-3AA8-466C-8C71-90FEFD694F17Q79782971-84242DF3-B248-4DBC-BE5A-87E81AE3467FQ80797079-77D7E488-06FF-47ED-BB38-469112D990F0Q81239860-02645F23-50A2-4609-AC38-F61175A8FA5BQ81436574-8AFD87A3-DFAB-46E8-ABFE-02FD29EE8A95Q87092630-B6974672-D801-4F0F-B385-A22C9092A33D
P50
name
Harry L Keyserling
@en
type
label
Harry L Keyserling
@en
prefLabel
Harry L Keyserling
@en